Search results for Mavenclad

Mavenclad helps MS patients keep cognitive skills sharp over 2 years

Among people with relapsing forms of multiple sclerosis (MS) and highly active disease, Mavenclad (cladribine) treatment resulted in stable or better cognitive function over two ye...

Developer creates under-the-tongue cladribine for testing in MS

A new formulation — a film that dissolves under the tongue — of cladribine for treating multiple sclerosis (MS) has moved closer to clinical testing, according to an update from it...

AAN2026 CLAD 5 years on. What to Do?

With Alemtuzumab about 50% of people need a thrid dose because of disease breakthrough and only about 50% of them would need a forth course because of disease breakthrough. The res...

Is ScandiLand Ready for Generic Cladribine?

The post below has very little to do with the title of my post but it looks at what happens after rituximab and they recon that cladribine is the next most cost effective drug. Peo...

AAN 2026. Cladribine takes time to kill..Think about this when switching

Is Cladribine a Suitable Strategy after Natalizumab in MS? Real-world Outcomes are reported here. What next if people have to switch from natalizumab and this study looks at cladri...

Frexalimab AAN20226

Frexalimab is an indirect B cell inhibitor. It block the natural signal that a B cell gets from T cells and antigen presenting cells as it blocks the ligand (binding bit) to the CD...

Ocrevus (ocrelizumab) for multiple sclerosis

Ocrevus (ocrelizumab) is an infusion therapy approved to treat adults with relapsing forms of MS and primary progressive MS. Administered via an intravenous infusion, the treatment...

Drilling Down on Cladribine biology

This study uses high end technology to delve into the “unclear” and the conclusion is that cladribine gives long-term depletion of memory B cells and then we can say “Should have g...

AAN 2026: Fenebrutinib outperforms Aubagio for treating relapsing MS

The experimental drug fenebrutinib was shown to significantly outperform Aubagio (teriflunomide), an approved therapy, in reducing relapses and MRI markers of disease activity in p...

Drug Effective In Slowing Progressive MS, Trial Shows

FRIDAY, May 29, 2026 — An already-approved MS drug can significantly slow progression in people with primary progressive multiple sclerosis (PPMS), according to a new study.Patien...

Switching made easier

Schoof LG, Hogenboom L, van Kempen ZL, Killestein J, van Oosten BW, Strijbis EM. Reinitiating ocrelizumab with a full 600 mg dose after extended treatment interruption: No increa...

Ocrelizumab Effective In Slowing Progressive MS, Trial Shows

FRIDAY, May 29, 2026 — An already-approved MS drug can significantly slow progression in people with primary progressive multiple sclerosis (PPMS), according to a new study. Patien...

Gute Nachrichten: EMA genehmigt Tolebrutinib

Yep the good news is that the EMA has approved the French Drug for progressive MS. This a Brutons Tyrosine kinase inhibitor that the FDA pushed back on. Will this arrive and make i...

Latest preclinical data support promise of CAR-M cell therapy LIB820

Liberate Bio’s investigational CAR-M cell therapy LIB820 may help successfully eliminate disease-driving B-cells in autoimmune diseases such as multiple sclerosis (MS) without caus...

CLADLad time Middle Eastern Style

ProfK is a CladLad and has been flying the flag for many years. I put this paper up as it reinforces what I was saying about breaks after anti-CD20. Someone asked me if we will eve...

Most of progression is due to the effects of lesions controlled by drugs that inhibit relapses

Signori A, Montobbio N, Bovis F, Ponzano M, Schiavetti I, Krenn A, Sormani MP. Uncoupling Relapse Reduction and Disability Progression: Evidence From Tolebrutinib Studies. Neurol C...

<![CDATA[FDA Approves Beqalzi for Relapsed or Refractory Mantle Cell Lymphoma, Inqovi in Combination with Venetoclax]...

<![CDATA[ Implications of Tecvayli Plus Darzalex Faspro Demonstrating 83% Reduction in Disease Progression or Death.]...